William P. Kane Jr - Feb 6, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Commercial Officer
Signature
/s/ Troy Ignelzi, Attorney-in-fact
Stock symbol
KRTX
Transactions as of
Feb 6, 2023
Transactions value $
$0
Form type
4
Date filed
2/7/2023, 05:16 PM
Previous filing
Aug 18, 2021
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Award $0 +17.7K $0.00 17.7K Feb 6, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Stock Option (Right to Buy) Award $0 +29.9K $0.00 29.9K Feb 6, 2023 Common Stock 29.9K $192.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 6, 2024, subject to continued service through such dates.
F2 25% of this option shall vest on February 6, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.